Partner Therapeutics, Inc. has disclosed post hoc data from the eNRGy clinical trial evaluating continued treatment with zenocutuzumab beyond radiographic disease progression in patients with neuregulin 1 fusion-positive non-small cell lung cancer. The analysis, presented at the 2026 International Association for the Study of Lung Cancer Targeted Therapies of Lung Cancer meeting, examined outcomes in patients who remained on zenocutuzumab after RECIST-defined progression. The data emerge in the context of zenocutuzumab’s United States Food and Drug Administration accelerated approval for NRG1 fusion-positive non-small cell lung cancer based on response rate and durability endpoints.
Why treatment beyond progression in NRG1 fusion-positive lung cancer challenges existing response paradigms
Treatment beyond progression remains a controversial concept in oncology, largely confined to select molecular subgroups where disease biology and progression patterns are heterogeneous rather than uniformly systemic. The eNRGy post hoc findings place neuregulin 1 fusion-positive non-small cell lung cancer squarely into that category. Unlike more common oncogenic drivers such as EGFR or ALK alterations, NRG1 fusions generate chimeric ligands that activate HER3 signaling through HER2-HER3 heterodimerization. This biology creates a dependency pattern that can persist even as isolated lesions evolve resistance or escape.
Industry observers note that RECIST progression is a blunt instrument in molecularly defined cancers, particularly when oligoprogression rather than diffuse failure dominates. In the eNRGy analysis, more than four out of five patients experienced oligoprogression rather than widespread disease acceleration. That distinction matters because oligoprogression suggests ongoing systemic disease control with localized resistance, a scenario in which continued targeted inhibition may retain value.
The implication is not that RECIST is wrong, but that its role as an automatic discontinuation trigger may be poorly suited to ultra-rare, fusion-driven tumors with limited alternative options. For clinicians managing NRG1 fusion-positive disease, the data provide structured evidence supporting a practice that has often occurred informally in clinic.
What is genuinely new versus incremental in the eNRGy post hoc analysis
The novelty of the eNRGy post hoc analysis lies less in raw efficacy metrics and more in treatment behavior over time. Zenocutuzumab had already demonstrated response activity sufficient for accelerated approval, but the durability of benefit beyond progression was not previously characterized in detail. The extension of median total exposure from approximately seven months pre-progression to nearly ten months overall reframes zenocutuzumab as a therapy that can deliver incremental disease control well beyond initial response.
Equally important is the qualitative nature of the benefit. Several patients remained on therapy for more than six months beyond progression, with some extending treatment by nearly two years or longer. These are not marginal extensions measured in weeks. They represent clinically meaningful periods of stability in a population with historically poor outcomes and limited post-progression options.
What remains incremental is the evidentiary weight. The analysis is post hoc, includes only 27 patients, and lacks a comparator arm. Regulatory watchers will be cautious in extrapolating broadly. Still, in rare oncology subtypes, incremental evidence often accumulates through such analyses rather than through large randomized trials that may never be feasible.
How zenocutuzumab compares with existing options after progression in NRG1 fusion-positive disease
NRG1 fusion-positive non-small cell lung cancer occupies a therapeutic blind spot. Standard chemotherapy, immunotherapy, and non-targeted regimens have shown low response rates, and no competing targeted therapies are currently approved for this population. That absence fundamentally alters the risk-benefit calculus of continuing a drug beyond progression.
Clinicians tracking the field point out that in more crowded molecular indications, treatment beyond progression is difficult to justify when multiple next-line agents are available. In contrast, NRG1 fusion-positive patients often face a stark choice between continuing a partially effective targeted therapy or reverting to regimens with historically poor efficacy.
Zenocutuzumab’s bispecific mechanism, targeting HER2-HER3 interactions rather than the fusion itself, may also contribute to sustained pathway suppression even as tumor clones diversify. This contrasts with kinase inhibitors where single-point mutations can rapidly abrogate drug binding. While resistance mechanisms in NRG1 fusion-positive disease remain incompletely characterized, the observed tolerability profile supports longer-term use in selected patients.
Clinical relevance of oligoprogression and local therapy integration
One of the most practice-shaping aspects of the analysis is the integration of local therapies alongside continued systemic treatment. A subset of patients underwent radiotherapy, gamma knife surgery, or surgical resection for progressing lesions while remaining on zenocutuzumab. This multimodal approach mirrors strategies used in EGFR- or ALK-driven lung cancer, where localized intervention can extend the life of a targeted therapy.
The relevance here is twofold. First, it confirms that disease control in NRG1 fusion-positive lung cancer can be compartmentalized rather than uniform. Second, it raises operational questions about how oncology teams coordinate imaging, intervention timing, and reimbursement for combined systemic and local strategies in ultra-rare populations.
From a health system perspective, these patients are likely to be managed in tertiary centers with molecular tumor boards, reinforcing the importance of specialized care pathways rather than community-standard algorithms.
Regulatory implications under accelerated approval frameworks
Zenocutuzumab’s approval pathway adds another layer of complexity. Accelerated approval based on response rate and duration of response places ongoing pressure on confirmatory evidence generation. Regulatory watchers suggest that while treatment beyond progression is unlikely to become a labeled indication, the data may inform real-world use and shape expectations for post-marketing commitments.
The challenge lies in defining what constitutes confirmatory benefit in a population where randomized trials are logistically difficult. Durable disease control beyond progression, particularly when supported by tolerability data, may contribute to a broader evidentiary narrative even if it does not directly satisfy traditional endpoints.
However, regulators will likely scrutinize whether extended treatment masks delayed toxicity or compromises patient safety. Continued pharmacovigilance and transparent reporting of adverse events will be essential as real-world exposure accumulates.
Safety profile considerations in prolonged zenocutuzumab exposure
Extended use inevitably shifts attention toward cumulative safety risks. The eNRGy analysis reported no discontinuations due to adverse events among patients treated beyond progression, suggesting that tolerability does not deteriorate over time in this selected cohort. Nevertheless, the known risks associated with HER2 and HER3 pathway inhibition remain clinically relevant.
Infusion-related reactions, interstitial lung disease, and cardiac dysfunction are not theoretical concerns. While incidence rates appear manageable, prolonged exposure increases the window for rare but serious events to emerge. Clinicians must balance the desire for extended disease control against the need for vigilant monitoring, particularly in patients with pre-existing pulmonary or cardiac vulnerability.
From an industry standpoint, the safety narrative will be as important as efficacy in sustaining confidence among prescribers and regulators alike.
Diagnostic and scalability challenges in identifying eligible patients
Another unresolved issue is identification. NRG1 fusions are rare and often missed without comprehensive molecular profiling that includes RNA-based sequencing. The need for combined DNA and RNA next-generation sequencing limits access in regions where such testing is not routinely reimbursed or available.
As zenocutuzumab use potentially extends beyond initial progression, diagnostic precision becomes even more critical. Treating beyond progression presupposes confidence in the underlying driver. False positives or incomplete profiling could lead to inappropriate therapy continuation with limited benefit.
Industry observers believe that broader adoption of RNA sequencing in lung cancer diagnostics will be a prerequisite for scaling NRG1-targeted strategies beyond academic centers.
What clinicians and regulators are likely to watch next
Several questions remain unanswered. Foremost among them is whether continued treatment beyond progression translates into overall survival benefit or sustained quality of life improvements. While such endpoints may be difficult to measure formally, real-world data will increasingly influence perception.
Resistance biology also looms large. Understanding why some patients derive prolonged benefit while others progress diffusely could guide patient selection and combination strategies. Exploratory biomarker work may prove more impactful than larger efficacy trials in this context.
Finally, the confirmatory trial pathway will remain under scrutiny. Regulators will expect Partner Therapeutics to demonstrate that zenocutuzumab’s benefit is durable, reproducible, and clinically meaningful across tumor types harboring NRG1 fusions.
Why treatment beyond progression may become an accepted strategy in NRG1 fusion-positive NSCLC despite regulatory gray zones
The eNRGy post hoc analysis does not redefine standards overnight, but it meaningfully shifts expectations around how zenocutuzumab can be used in clinical practice. For a population with few alternatives, evidence supporting continued benefit beyond progression carries disproportionate weight. The findings reinforce a growing recognition that molecularly defined cancers require equally nuanced treatment frameworks, even when regulatory labels lag behind clinical reality.
Partner Therapeutics’ zenocutuzumab data adds nuance to progression-driven treatment decisions in NRG1-positive lung cancer added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →